GILEAD SCIENCES, INC. Inventory Write-down
GILEAD SCIENCES, INC. (GILD) reported Inventory Write-down of $228.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2022-02-23
- GILEAD SCIENCES, INC. inventory write-down for fiscal 2021 was $228.00M, a 165.12% increase from fiscal 2020.
- GILEAD SCIENCES, INC. inventory write-down for fiscal 2020 was $86.00M, a 86.75% decline from fiscal 2019.
- GILEAD SCIENCES, INC. inventory write-down for fiscal 2019 was $649.00M, a 13.46% increase from fiscal 2018.
- GILEAD SCIENCES, INC. inventory write-down for fiscal 2018 was $572.00M.
| Period end | Inventory Write-down 12 month |
|---|---|
| 2021-12-31 | $228.00M 10-K · filed 2022-02-23 |
| 2020-12-31 | $86.00M 10-K · filed 2022-02-23 |
| 2019-12-31 | $649.00M 10-K · filed 2022-02-23 |
| 2018-12-31 | $572.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |